Laurie Barclay, MD Aug. 1, 2002 —
Inhaled iloprost was effective in improving symptoms and walking distance in people with severe pulmonary hypertension, according to the results of a randomized, placebo-controlled trial in the Aug. 1 issue of the New England Journal of Medicine.
The benefit was similar to that of continuous infusion of epoprostenol. “Uncontrolled studies suggested that aerosolized iloprost, a stable analogue of prostacyclin, causes selective pulmonary vasodilatation and improves hemodynamics and exercise therapy in patients with pulmonary hypertension,” write Horst Olschewski, MD, and colleagues from the Aerosolized Iloprost Randomized Study Group.
תגובות רוצה להצטרף לדיון?
יש להתחבר כדי להגיב.
התחבראין תגובות עדיין. היה הראשון להגיב!